Vanda Pharmaceuticals (VNDA) Gross Margin (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported Gross Margin of 93.89% for Q1 2026, up 93.0% on a YoY basis from 48.65% in Q1 2025, and up 0.63% sequentially from 93.3% in Q4 2025.
Vanda Pharmaceuticals (VNDA) Gross Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 14 years of Gross Margin data on file, last reported at 93.89% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 93.0% year-over-year to 93.89%; the trailing twelve-month figure through Mar 2026 stood at 94.18% (down 16.0% YoY), and the FY2025 full-year result was 93.96%, down 34.0% from the prior year.
- Gross Margin rose to 93.89% in Q1 2026, from 93.3% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 95.13% in Q4 2024 to a low of 90.32% in Q3 2022.
- A 5-year average of 92.82% and a median of 92.75% in 2024 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin surged 277 bps in 2024 and slumped 183 bps in 2025, its largest moves.
- Tracing VNDA's Gross Margin over 5 years: stood at 90.33% in 2022, then grew by 2 bps to 92.36% in 2023, then rose by 3 bps to 95.13% in 2024, then fell by 2 bps to 93.3% in 2025, then advanced by 1 bps to 93.89% in 2026.
- Business Quant data shows VNDA's Gross Margin at 93.89% in Q1 2026, 93.3% in Q4 2025, and 94.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | 93.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.89% |
| Dec 31, 2025 | 93.30% |
| Sep 30, 2025 | 94.75% |
| Jun 30, 2025 | 94.80% |
| Mar 31, 2025 | 92.96% |
| Dec 31, 2024 | 95.13% |
| Sep 30, 2024 | 94.65% |
| Jun 30, 2024 | 94.59% |
| Mar 31, 2024 | 92.75% |
| Dec 31, 2023 | 92.36% |
| Sep 30, 2023 | 92.11% |
| Jun 30, 2023 | 92.40% |
| Mar 31, 2023 | 92.36% |
| Dec 31, 2022 | 90.33% |
| Sep 30, 2022 | 90.32% |
| Jun 30, 2022 | 90.59% |
| Mar 31, 2022 | 90.59% |
| Dec 31, 2021 | 90.83% |
| Sep 30, 2021 | 90.30% |
| Jun 30, 2021 | 90.33% |